Qualification opinion for the iBox Scoring System as a secondary efficacy endpoint in clinical trials investigating novel immunosuppressive medicines in kidney transplant patients(IBox 评分系统作为肾移植患者新型免疫抑制药物临床试验次要疗效终点的资格审查意见)